CELG News and Press, Celgene Corporation From 03/26/20

This article is first in a series that provides an ongoing analysis of the changes made to Wedgewood Partners’ 13F stock portfolio on a quarterly basis. It is based on David Rolfe’s regulatory 13F Form filed on 02/14/2020. The 13F portfolio value decreased ~13%, from $1.13B to ...

BeiGene (NASDAQ: BGNE ) announces a supply disruption in Abraxane (nanoparticle albumin-bound paclitaxel) due to the suspension of importation instituted by the China National Medical Products Administration. The agency took action after inspecting Bristol-Myers Squibb's (NYSE: BMY ) manuf...

Quick Take Keros Therapeutics ( KROS ) has filed to raise $86.25 million in an IPO of its common stock, according to an S-1 registration statement . The firm is a clinical stage biopharma developing a pipeline of drug candidates for the treatment of hematological and musculoskeletal disor...

This article is part of a series that provides an ongoing analysis of the changes made to John Paulson's 13F stock portfolio on a quarterly basis. It is based on Paulson's regulatory 13F Form filed on 02/14/2020. Please visit our Tracking John Paulson's Paulson & Company Portfolio serie...

This article is part of a series that provides an ongoing analysis of the changes made to George Soros's 13F stock portfolio on a quarterly basis. It is based on George Soros's regulatory 13F Form filed on 02/14/2020. Please visit our Tracking Soros Fund Management Holdings article for an ...

Jefferies' Michael Yee says investors believe that Gilead Sciences ( GILD +0.6% ) is an acquisition target considering its near-term share performance (at the same level as three years ago with some volatility thrown in) and tepid growth prospects (little or no topline increase expected th...

Source : ClearBridge Investments Editor's Note : The summary bullets for this article were chosen by Read more ...

Quick Take Arcutis Biotherapeutics ( ARQT ) intends to raise $125 million from the sale of its common stock in an IPO, per an amended registration statement . The company is advancing a pipeline of treatment candidates for various skin conditions. For its lead candidate, ARQT plans to h...

Investment Thesis Last week, in my research note on direct Trillium (TRIL) rival, Forty Seven (FTSV), I argued that Forty Seven was the pick of the immunology companies developing CD47 antibodies to treat various forms of cancer - including hematologic malignancies, diffuse large B-cell ly...

Chinese drug developer BeiGene (NASDAQ: BGNE)  announced on Monday strong clinical results for its cancer immunotherapy, tislelizumab. A Phase 3 trial tested the drug alongside two other chemotherapy treatments in patients with non-small cell lung cancer and successfully met its primary ...